Name |
Yuguo Chen |
Title |
M.D., Ph.D., Professor, Chief Physician, FACC, FESC, FSCAI |
Areas of Focus |
Diagnosis and differential diagnosis of acute chest pain, Interventional diagnosis and treatment of coronary heart disease, Cardiopulmonary Cerebral Resuscitation |
Professor Yuguo Chen takes the position of President of Qilu Hospital of Shandong University and Director of Clinical Research Center for Emergency and Critical Care Medicine of Shandong Province. He is an interventional cardiologist and an Emergency Medicine specialist, Professor of Emergency Medicine, Cardiology and Epidemiology of Shandong University, FESC, FACC, FSCAI. He also serves as the President of Chinese Society of Emergency Medicine, President-elect of Chest Pain society of Chinese Medical Association, and so on.
Professor Chen’s basic research concentrates on cardiovascular diseases and cardiopulmonary resuscitation. He has focused on the field of Acetaldehyde Dehydrogenase (ALDH2) and cardiovascular diseases for ten years, and has revealed important cardioprotective roles of ALDH2 in several pathological conditions, including ischemia-reperfusion, hyperglycemia, alcoholic cardiomyopathy. New targets for organ protection in cardiopulmonary resuscitation is his new focal point of research.
During Recent seven years, he has spared lots of efforts to do clinical researches. He is conducting the following five multi-center clinical studies (including 1 RCT). EMPACT study, aiming to evaluation the current situation and explore novel methods management for the clinical practice of triage, diagnosis and treatment of chest pain, is the first large-scale chest pain cohort in China. BASIC study, supported by the Ministry of Science and Technology, will be the most authoritative study about the current situation of cardiac arrest in China. BIPass study, supported by the “Precision Medicine” project of National Key Research and Development Program of China, is focusing on the precision diagnosis of coronary artery disease. EAST-STEMI study is aiming to evaluate the antithrombotic drug use in acute myocardial infarction patients in China. EMS-AHF, the RCT, is studying the early use of Levosimendan on heart failure patients.
He contributes greatly to the development of Emergency Medicine in China. In 2016, he initiated a program to investigate the current situation of 2000 Emergency Departments in China. He advocates improving the Emergency service system in China and emphasizes the construction of prehospital first-aid service and chest pain centers. Based on this, he has established “Chinese Emergency Medicine Alliance”, getting the emergency departments together to improve the quality of emergency medical care and to build up a distinct Chinese Emergency Service System.